What is Charco Neurotech?
Founded in 2019, Charco Neurotech operates at the intersection of neuroscience and engineering. The company is dedicated to developing non-invasive, wearable systems designed to mitigate the debilitating symptoms of Parkinson's disease. By leveraging advanced sensory technology, the startup aims to restore mobility and confidence for patients, effectively bridging the gap between academic research and practical, patient-centric clinical solutions. Its position as a university-linked spinout provides a robust foundation for long-term innovation in the neuro-tech domain.
How much funding has Charco Neurotech raised?
Charco Neurotech has raised a total of $10M across 1 funding round:
Angel/Seed
$10M
Angel/Seed (2021): $10M with participation from Amadeus Capital Partners, Mint Venture Partners, Parkwalk Advisors, and Edge Capital Group
Key Investors in Charco Neurotech
Amadeus Capital Partners
Amadeus Capital Partners is a London-based global technology venture capital firm that invests in high-growth companies from seed to later stages across sectors such as artificial intelligence, digital health, and deep tech.
Mint Venture Partners
Mint Venture Partners is a global venture platform focused on creating, building, accelerating, and investing in biotech and healthcare startups to drive advancements in the industry.
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deep-tech innovations emerging from the UK's top universities, bridging the gap between academic research and commercial success.
What's next for Charco Neurotech?
With this major enterprise-level funding, Charco Neurotech is expected to transition from its initial research phase into a more aggressive commercialization and clinical validation cycle. The strategic allocation of these funds will likely focus on scaling manufacturing capabilities, securing regulatory approvals, and expanding its research team to refine its core technology. As the company matures, it will likely seek further partnerships with healthcare providers to integrate its solutions into standard care pathways, ultimately aiming to establish a new benchmark for Parkinson's symptom management on a global scale.
See full Charco Neurotech company page
